Cooper, J.S.

patient revascularisation abciximab mortality trial 30 days troponin gusto iv-acs 1- year mortality syndrome gusto /iiia iv-ac elevation infarction treatment study group angina investigator placebo inhibitor effect infusion 1 year survival circulation propensity score randomised platelet heart 48- hour abciximab result therapy 48- follow-up difference baseline st-segment elevation non-st elevation st-segment outcome benefit 24- hour infusion 3 treatment groups lancet glycoprotein death troponin t st elevation intervention 48 hours 24- angiography revascularization propensity strategy 48- hour infusion placebo group analyses depression score analysis multivariable heparin level signi st depression 30- day survivors grant support multivariable analyses value non-st randomized 24- hour abciximab <0.001 hospital receptor association survival benefit